Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer by Rothschedl, E.
 Horizon Scanning 
in Oncology 
Olaparib (Lynparza®) as first-
line maintenance therapy in 
patients with newly 
diagnosed advanced ovarian 
cancer 
 
 
DSD: Horizon Scanning in Oncology No. 86 
ISSN online 2076-5940 
 Horizon Scanning 
in Oncology 
Olaparib (Lynparza®) as first-
line maintenance therapy in 
patients with newly 
diagnosed advanced ovarian 
cancer 
 
 
Vienna, March 2019 
 Institute for Health Technology Assessment 
Ludwig Boltzmann Gesellschaft  
 
Authors:  Dr. Eleen Rothschedl 
Internal review: Priv.-Doz. Dr. phil. Claudia Wild; Nicole Grössmann, MSc 
External review: Univ.-Prof. Dr. Alexander Reinthaller 
Klinische Abteilung für Allgemeine Gynäkologie und Gynäkologische Onkologie, Universitätsklinik 
für Frauenheilkunde, Medizinische Universität Wien 
 
 
 
 
 
DISCLAIMER 
This technology summary is based on information available at the time of research and on a limited literature search.  
It is not a definitive statement on safety, effectiveness or efficacy and cannot replace professional medical advice nor 
should it be used for commercial purposes. 
The HTA Core Model® for Rapid Relative Effectiveness for Pharmaceuticals, developed within EUnetHTA 
(www.eunethta.eu), has been utilised when producing the contents and/or structure of this work. A working version 
(unpublished) of V3.0 of the Model was used. Use of the HTA Core Model® does not guarantee the accuracy, 
completeness, quality or usefulness of any information or service produced or provided by using the Model. 
 
 
 
CONTACT INFORMATION 
Publisher: 
Ludwig Boltzmann Gesellschaft GmbH 
Nußdorferstr. 64, 6 Stock, A-1090 Vienna 
http://www.lbg.ac.at/de/lbg/impressum 
Responsible for Contents: 
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)  
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicise  
the research results of the Ludwig Boltzmann Institute of Health Technology Assessment. 
Decision support documents of the LBI-HTA are only available to the public via the Internet at 
http://eprints.hta.lbg.ac.at. 
DSD: Horizon Scanning in Oncology No. 86 
ISSN-online: 2076-5940 
http://eprints.hta.lbg.ac.at/view/types/ 
© 2019 LBI-HTA – All rights reserved 
Olaparib (Lynparza
®
) as first-line maintenance therapy in patients with 
newly diagnosed advanced ovarian cancer 
LBI-HTA | 2019 3 
Abstract 
Introduction 
In December 2018, the US Food and Drug Administration approved 
olaparib, a poly polymerase (PARP) inhibitor, for the first-line maintenance 
treatment of adult patients with deleterious or suspected deleterious 
germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian 
tube or primary peritoneal cancer, who are in complete response (CR) or 
partial response (PR) to first-line platinum-based chemotherapy. To date, 
olaparib has not yet been approved by the European Medicines Agency for 
the assessed indication. 
Methodology 
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer, resulting in 153 references overall. A quality 
assessment was conducted to assess the risk of bias at the study level based 
on the EUnetHTA internal validity for randomised controlled trials. The 
Magnitude of Clinical Benefit Scale developed by the European Society for 
Medical Oncology was not applicable due to lack of median progression-free 
survival (PFS) – and overall survival (OS) data. 
Results from the SOLO1 trial 
The SOLO1 trial evaluated the efficacy and safety of olaparib first-line 
maintenance therapy in patients with newly diagnosed advanced ovarian 
cancer, primary peritoneal cancer or fallopian tube cancer and a BRCA1/2 
mutation, who had a CR or PR after platinum-based chemotherapy. Investi-
gator-assessed analysis showed that the Kaplan-Meier estimate of the rate of 
freedom from disease progression and from death at three years was 60% in 
the olaparib group versus 27% in the placebo group. According to the analy-
sis assessed by blinded independent central review, the Kaplan-Meier esti-
mate of the rate of freedom from disease progression and from death at three 
years was 69% in the olaparib group versus 35% in the placebo group. A sen-
sitivity analysis of investigator-assessed PFS showed that the median PFS 
was 36.1 months longer in patients of the olaparib group than in patients of 
the placebo group. An interim analysis of OS data showed a Kaplan-Meier 
estimate of the rate of freedom from death at three years of 84% (olaparib 
group) vs 80% (placebo group). The median time to the first subsequent 
therapy or death was longer in olaparib group patients (51.8 months) than in 
placebo group patients (15.1 months). Serious adverse events (AEs) occurred 
in 21% of patients receiving olaparib and 12% of patients who received pla-
cebo. No AEs that occurred during the study intervention led to death. 
Conclusion 
SOLO1 trial results showed a benefit with olaparib first-line maintenance 
therapy in delay of disease progression in patients with newly diagnosed 
ovarian cancer and BRCA1/2 mutation. However, the trial is currently ongo-
ing, the presented data are the primary analysis data, and interim OS data 
are immature. HRQoL data also derives from primary analysis and the de-
tected between-group difference was not considered to be clinically mean-
ingful. Final analysis data from the SOLO1 trial is pending and may con-
firm the clinical benefit of olaparib first-line maintenance therapy. Further 
investigation of olaparib first-line maintenance therapy in phase III trials, 
long-term data, as well as a direct comparison of olaparib with different 
PARP inhibitors are warranted to determine the optimal treatment for this 
patient population.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used to structure this report [1]. The Model organises 
HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is olaparib? 
A0022 Who manufactures olaparib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has olaparib received marketing authorisation? 
Health problem and current use 
A0002 What is ovarian cancer? 
A0004 What is the natural course of ovarian cancer? 
A0006 What are the consequences of ovarian cancer for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of ovarian cancer? 
A0003 What are the known risk factors for ovarian cancer? 
A0024 
How is ovarian cancer currently diagnosed according to published guidelines and in 
practice? 
A0025 
How is newly diagnosed ovarian cancer currently managed according to published 
guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of olaparib on mortality? 
D0006 How does olaparib affect progression (or recurrence) of ovarian cancer? 
D0005 
How does olaparib affect symptoms and findings (severity, frequency) of ovarian 
cancer? 
D0011 What is the effect of olaparib on patients ̕ body functions? 
D0012 What is the effect of olaparib on generic health-related quality of life? 
D0013 What is the effect of olaparib on disease-specific quality of life? 
Safety 
C0008 How safe is olaparib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying olaparib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of olaparib? 
A0021 What is the reimbursement status of olaparib? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
 
Generic/Brand name/ATC code:  
Olaparib/Lynparza
®
/L01XX46 
 
B0001: What is olaparib? 
Olaparib (Lynparza
®
) is a small molecule inhibitor of the human poly 
(ADP-ribose) polymerase enzymes (PARP-1, PARP-2 and PARP-3) with po-
tential chemosensitising, radiosensitising and antineoplastic activities. It 
has been shown to inhibit tumour growth in vivo (as well as the growth of se-
lected tumour cell lines in vitro) either by single-use or in combination with 
established chemotherapies. Olaparib selectively binds and inhibits PARPs, 
which are required for the efficient repair of deoxyribonucleic acid (DNA) 
single-strand breaks. By the inhibition of PARP, the cytotoxicity of DNA-
damaging agents may be enhanced and tumour cell chemoresistance and ra-
dioresistance may be reversed [2, 3].  
Prior to the initiation of olaparib treatment, the patients’ breast cancer sus-
ceptibility gene (BRCA) mutation status should be determined by using an 
appropriately validated test. If the patients have a confirmed deleterious or 
suspected deleterious BRCA mutation in either the germline or the tumour, 
they are eligible for olaparib therapy [2]. 
The recommended dose of olaparib is 300 mg (two 150 mg tablets) taken 
twice daily, equivalent to a total daily dose of 600 mg [2]. In Austria, 
Lynparza
® 
is available as tablets (100 and 150 mg) and capsules (50 mg) [4]. 
There are important differences in posology between olaparib capsules and 
tablets; olaparib capsules should not be substituted for olaparib tablets due 
to differences regarding the dosing and bioavailability of each formulation. 
The specific dose recommendations for each formulation should be fol-
lowed. Olaparib is for oral use; the tablets should be swallowed whole and 
not be chewed, crushed, dissolved or divided. Lynparza
®
 tablets may be tak-
en without regard to meals [2]. 
Olaparib treatment should be started no later than eight weeks after comple-
tion of the final dose of the platinum-containing chemotherapy; it is recom-
mended that the treatment should be continued until disease progression. In 
case of the occurrence of adverse reactions (e.g., nausea, vomiting, diarrhoea 
and anaemia), olaparib treatment may be interrupted and dose reduction 
can be considered. The concomitant use of strong or moderate Cyto-
chrome(CYP)3A inhibitors is not recommended and the use of alternative 
agents should be considered [2].  
Olaparib is contraindicated in case of hypersensitivity to the active sub-
stance or to any of the excipients (see Table 4), and breast-feeding during 
treatment and one month after the last dose [2]. 
 
A0022: Who manufactures olaparib? 
AstraZeneca. Olaparib is being co-developed by AstraZeneca and Merck [5]. 
olaparib is a PARP 
inhibitor  
 
PARP are required for 
the efficient repair of 
DNA single-strand 
breaks 
 
BRCA mutation status 
needs to be determined 
prior to treatment start 
300 mg olaparib orally 
twice daily 
 
CAVE: dosing 
differences between 
tablets and capsules! 
olaparib initiation 
within 8 weeks after 
completion of 
chemotherapy 
contraindications: 
hypersensitivity, breast-
feeding 
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3 Indication 
A0007: What is the target population in this assessment? 
Olaparib (Lynparza
®
) is indicated as first-line maintenance therapy in pa-
tients with newly diagnosed advanced ovarian cancer, primary peritoneal 
cancer or fallopian tube cancer (or a combination thereof) with a germline 
or somatic mutation in BRCA1, BRCA2, or both (BRCA1/2) who had a 
complete response (CR) or partial response (PR) after platinum-based 
chemotherapy [5]. 
 
 
4 Current regulatory status 
A0020: For which indications has olaparib received marketing authorisa-
tion? 
To date, olaparib (Lynparza
®
) has not been approved by the European Med-
icines Agency (EMA) for the assessed indication. The EMA granted market-
ing authorisation for Lynparza
®
 as monotherapy for the maintenance treat-
ment of adult patients with platinum-sensitive relapsed BRCA-mutated 
(germline and/or somatic) high grade serous epithelial ovarian, fallopian 
tube or primary peritoneal cancer, who are in response (CR or PR) to plati-
num-based chemotherapy [6].  
In December 2018, the U.S. Food and Drug Administration (FDA) approved 
olaparib (Lynparza
®
) for the first-line maintenance treatment of adult pa-
tients with deleterious or suspected deleterious germline or somatic BRCA-
mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube 
or primary peritoneal cancer, who are in CR or PR to first-line platinum-
based chemotherapy. Patients with gBRCAm advanced epithelial ovarian, 
fallopian tube or primary peritoneal cancer should be selected for therapy 
based on an FDA-approved companion diagnostic [7]. 
The FDA additionally granted marketing authorisation for the following in-
dications [8]: 
 As maintenance treatment of adult patients with recurrent epitheli-
al ovarian, fallopian tube or primary peritoneal cancer, who are in 
CR or PR to platinum-based chemotherapy 
 For the treatment of adult patients with deleterious or suspected 
deleterious gBRCAm advanced ovarian cancer who have been treat-
ed with three or more prior lines of chemotherapy. Patients should 
be selected for therapy based on an FDA-approved companion di-
agnostic. 
 For the treatment of patients with deleterious or suspected delete-
rious gBRCAm, human epidermal growth factor receptor 2 
(HER2)-negative metastatic breast cancer who have been treated 
with chemotherapy in the neoadjuvant, adjuvant or metastatic set-
ting. Patients with hormone receptor (HR)-positive breast cancer 
should have been treated with a prior endocrine therapy or be con-
women with newly 
diagnosed ovarian 
cancer and a BRCA1/2 
mutation with CR or PR 
after platinum-based 
chemotherapy 
not approved by the 
EMA for the assessed 
indication 
FDA-approved for first-
line maintenance 
treatment since 12/2018 
further FDA-approved 
indications 
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sidered inappropriate for endocrine therapy. Patients should be se-
lected for therapy based on an FDA-approved companion diagnos-
tic. 
 
 
5 Burden of disease 
A0002: What is ovarian cancer? 
In Austria, ovarian cancer is the seventh most common cancer in women; 3% 
of cancer cases in women are ovarian cancers [9]. Ovarian cancer develops in 
the fallopian tubes (70%), ovaries (30%) and, in rare cases, derives from the 
peritoneum (primary peritoneal cancer). 
The majority of tumours (approximately 90%) are of epithelial origin. The 
following subtypes can be distinguished: serous-papillary (which is the most 
common histological type), endometrioid, clear cell, mucinous, Brenner 
(transitional cell), mixed epithelial tumours, undifferentiated and unclassi-
fied [10, 11]. 
 
A0004: What is the natural course of ovarian cancer? 
In Austria, 650 women were affected by ovarian cancer in 2016; 519 women 
died from the disease. Approximately 50% of the women were diagnosed 
with ovarian cancer when the tumour had already metastasised: 25% at re-
gional tumour stage, 21% at disseminated tumour stage (one-third of the 
tumours could not be assigned). The relative survival rate following diagno-
sis in patients with ovarian cancer (2009–2013) is 75.5% at one year, 55.5% 
at three years and 44.3% at five years. In 2016, the age-standardised mortali-
ty rate (European Standard Population, 2013) was 10.7 per 100,000 women 
per year [9]. 
Despite the performance of an optimal upfront surgery and the administra-
tion of front-line chemotherapy with a paclitaxel- and carboplatin-
containing regimen, approximately 70% of patients have a relapse within 
the first three years [10].  
 
A0006: What are the consequences of ovarian cancer for the society? 
A0023: How many people belong to the target population? 
The age-standardised incidence rate (European Standard Population, 2013) 
of ovarian cancer in Austria is 13.8 per 100,000 women per year [9]. In 2016, 
650 women were newly diagnosed with the disease. 
In the US, the number of new cases of ovarian cancer was 11.6 per 100,000 
women per year; approximately 1.3% of women will be diagnosed with ovar-
ian cancer at some point during their lifetime (based on data from 2013–
2015). The median age at diagnoses of ovarian cancer is 63 years; the disease 
is most frequently diagnosed among women aged between 55 and 64 years. 
The percentage of ovarian cancer deaths is highest among patients aged 65 
to 74 years, with a median age at death of 70 years. The number of deaths 
was 7.2 per 100,000 women per year [12]. 
7th most common cancer 
in Austria 
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A0005: What are the symptoms and the burden of ovarian cancer? 
The clinical presentation of patients with epithelial ovarian carcinoma, fal-
lopian tube carcinoma and peritoneal carcinoma could be either acute or 
subacute. In some cases, the disease is discovered incidentally in the course 
of a surgery performed for another indication.  
The symptoms associated with ovarian carcinoma, fallopian tube carcinoma 
and peritoneal carcinoma are nonspecific and may also be caused by uro-
logic, gastrointestinal or other conditions. If symptoms are of new onset, co-
exist with other symptoms, occur almost daily, and are more severe than ex-
pected, further evaluation is warranted. Patients with an acute presentation 
are typically affected by advanced disease and present with conditions that 
require urgent care, including pleural effusion (causing shortness of breath), 
bowel obstruction (severe nausea and vomiting) or, infrequently, venous 
thromboembolism [13]. 
Most commonly, affected women present in a clinically subacute manner, 
including the following symptoms: 
 An adnexal mass, discovered on pelvic examination or imaging per-
formed due to symptoms of pelvic pain or pressure or found on rou-
tine pelvic examination. In patients with advanced disease, the pel-
vic mass may extend beyond the adnexa. 
 Pelvic and abdominal symptoms such as bloating, urinary urgency 
or frequency, difficulty eating or feeling full quickly, and pelvic or 
abdominal pain 
 Pelvic pain and pelvic mass 
 Abdominal distension due to ascites or bulky abdominal disease 
 Atypical glandular cells on cervical cytology (infrequent) 
 Paraneoplastic symptoms: cerebellar degeneration, polyneuritis, 
dermatomyositis, hemolytic anemia, disseminated intravascular co-
agulation, acanthosis, or nephrotic syndrome) (occurring rarely) 
 Palpable inguinal or cervical lymphadenopathy (uncommon)[13]. 
 
A0003: What are the known risk factors for ovarian cancer? 
The risk for ovarian cancer is increased by early menarche and late meno-
pause, infertility, increasing age, endometriosis and polycystic ovarian syn-
drome, obesity, cigarette smoking (mucinous carcinoma) and, possibly, the 
use of talcum powder. Furthermore, women who use an intrauterine device, 
who receive postmenopausal hormone therapy or who are affected by heredi-
tary ovarian cancer syndromes (BRCA gene mutations, Lynch syndrome) 
have a higher risk of developing ovarian cancer [10, 13, 14]. 
Factors that are protective or decrease the risk for ovarian cancer, respec-
tively, include the use of oral contraceptives, tubal ligation, breastfeeding, sup-
pression of ovulation and previous pregnancy [10, 13, 14]. 
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A0024: How is ovarian cancer currently diagnosed according to published 
guidelines and in practice? 
After conducting a full clinical assessment, serum CA-125 levels are meas-
ured. Although CA-125 is not specific for ovarian cancer (levels may also be 
raised in non-gynaecological malignancies and benign disease), it is elevated 
in about 85% of patients with advanced ovarian cancer.  
For women with suspected ovarian cancer, ultrasonography of the abdomen 
and the pelvis is recommended, and transvaginal ultrasonography improves 
the differentiation between malignant and benign conditions. Based on clin-
ical factors, ultrasound examination and the measurement of the CA-125 
level, a “risk of malignancy index” can be calculated. To determine the ex-
tent of the disease, a computed tomography (CT) should be conducted, as 
well as an CT or X-ray of the chest to verify the presence of pleural effusions 
and the extension of the disease above the diaphragm [10]. 
Ovarian cancer, fallopian tube cancer and peritoneum cancer are surgically 
staged according to the 2017 International Federation of Gynecology and 
Obstetrics (FIGO) system, representing the most powerful indicator of 
prognosis. The system includes the following stages [15]: 
 Stage I:  Tumour limited to ovaries (one or both) or fallopian 
tube(s) 
IA: Tumour limited to one ovary (capsule intact) or fallopian 
tube; no tumour on ovarian or fallopian tube surface; no 
malignant cells in ascites or peritoneal washings 
IB: Tumour limited to both ovaries (capsules intact) or  
fallopian tubes; no tumour on ovarian or fallopian tube 
surface; no malignant cells in ascites or peritoneal wash-
ings 
IC: Tumour limited to one or both ovaries or fallopian tubes,  
 with any of the following: 
 IC1: Surgical spill 
IC2: Capsule ruptured before surgery or tumour on ovari-
an or fallopian tube surface 
 IC3: Malignant cells in ascites or peritoneal washings 
 Stage II: Tumour involves one or both ovaries or fallopian tubes 
with  
 pelvic extension below pelvic brim or primary peritoneal  
cancer 
IIA: Extension and/or implants on the uterus and/or fallopian  
  tube(s) and/or ovaries 
IIB: Extension to and/or implants on other pelvic tissues 
 Stage III: Tumour involves one or both ovaries or fallopian tubes, or 
  primary peritoneal cancer, with microscopically  
  confirmed peritoneal metastasis outside the pelvis and/or  
  metastasis to the retroperitoneal (pelvic and/or  
  para-aortic) lymph nodes 
IIIA1: Positive retroperitoneal lymph nodes only  
(histologically confirmed) 
  IIIA1i: Metastasis up to and including 10 mm in greatest  
dimension 
IIIA1ii: Metastasis more than 10 mm in greatest dimension 
IIIA2: Microscopic extrapelvic (above the pelvic brim)  
full clinical assessment, 
CA-125 level 
measurement 
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Olaparib (Lynparza
®
) as first-line maintenance therapy in patients with 
newly diagnosed advanced ovarian cancer 
LBI-HTA | 2019 13 
peritoneal involvement with or without positive retro-
peritoneal lymph nodes 
IIIB: Macroscopic peritoneal metastasis beyond pelvis 2 cm or  
    less in greatest dimension with or without metastasis to 
   the retroperitoneal lymph nodes 
  IIIC: Macroscopic peritoneal metastasis beyond the pelvis  
more than 2 cm in greatest dimension with or without   
metastasis to the retroperitoneal lymph nodes (includes  
extension of tumour to capsule of liver and spleen with  
out parenchymal involvement of either organ) 
 Stage IV: Distant metastasis, including pleural effusion with  
   positive cytology; liver or splenic parenchymal metastsis; 
metastasis to extra-abdominal organs (including ingui-
nal   lymph nodes and lymph nodes outside the ab-
dominal  cav ity); and transmural involvement of intes-
tine 
IVA: Pleural effusion with positive cytology 
IVB: Liver or splenic parenchymal metastases; metastases to  
extra-abdominal organs (including inguinal lymph nodes 
and lymph nodes outside the abdominal cavity); transmu-
ral involvement of intestine. 
Since many of the symptoms associated with ovarian cancer, fallopian tube 
cancer and peritoneal cancer are nonspecific, the differential diagnosis of 
the diseases varies with the clinical presentation. If an adnexal mass is pre-
sent, the first step is to confirm the presence and location of the mass by us-
ing pelvic imaging, usually ultrasound. Benign, malignant or borderline 
conditions can be distinguished in regard to the differential diagnosis of ad-
nexal mass. In patients who present with abdominal distension or ascites in 
the absence of an adnexal mass, evaluation for other conditions should be 
performed. If women present with symptoms associated with ovarian cancer 
and/or abdominal distension or ascites, and elevated tumour markers (which 
are associated with ovarian cancer), a diagnostic laparoscopy should be con-
sidered as a part of the diagnostic evaluation [13]. 
 
 
6 Current treatment 
A0025: How is newly diagnosed ovarian cancer currently managed according 
to published guidelines and in practice? 
According to the European Society for Medical Oncology (ESMO) [10], the 
aim for patients with advanced epithelial ovarian cancer is the complete cy-
toreduction of all macroscopic visible disease, which is associated with a sig-
nificant increase in overall survival (OS) and progression-free survival 
(PFS). Optimal cytoreduction is defined as total macroscopic tumour clear-
ance with no residual visible disease. For patients with poor performance 
status at the time of presentation and those with very extensive tumour dis-
semination, the use of neoadjuvant chemotherapy with interval surgery is of-
fered. 
differential diagnosis 
varies with the clinical 
presentation 
ESMO 
recommendations 
 
 
 
optimal cytoreduction 
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Since the risks of recurrence of disease spread beyond the ovary are substan-
tial, the ESMO recommends chemotherapy for front-line treatment of pa-
tients with epithelial ovarian cancer and FIGO stage II-IV post surgery. The 
standard chemotherapeutical regimen is a combination of paclitaxel (175 
mg/m2) and carboplatin AUC 6–5 administered intravenously (IV) every 
three weeks for usually six cycles. For patients who develop an allergy to 
paclitaxel or who do not tolerate paclitaxel, a combination therapy of docet-
axel-carboplatin or pegylated liposomal doxorubicin-carboplatin can be con-
sidered alternatively. 
The Society of Gynecologic Oncology (SGO) and the American Society of 
Clinical Oncology (ASCO) recommend the following approach for patients 
with newly diagnosed or suspected stage IIIC or IV epithelial ovarian can-
cer, fallopian tube cancer or primary peritoneal cancer [16]: 
 Prior to therapy initiation, it should be evaluated whether patients 
with suspected stage IIIC or IV invasive epithelial ovarian cancer 
are eligible for primary cytoreductive surgery (PCS). 
 To assess the extent of the disease and the feasibility of surgical re-
section, a CT of the abdomen and pelvis (including the use of an 
oral and IV contrast) and chest imaging should be performed. 
 Patients with a high perioperative risk profile or a low likelihood of 
achieving cytoreduction to <1 cm should receive neoadjuvant 
chemotherapy (NACT). 
 NACT or PCS may be offered to patients who are eligible for PCS. 
However, according to the external reviewer, PCS is the preferred 
approach in patients who are eligible for this treatment option. 
NACT is associated with less peri- and postoperative morbidity and 
mortality, and shorter hospitalisation; PCS, if successful, seems to 
offer superior survival. 
 In women who have a high likelihood of achieving cytoreduction to 
<1 cm with acceptable morbidity, PCS is recommended over 
NACT. 
 For women who are eligible for PCS, but who are deemed unlikely 
to achieve cytoreduction <1 cm, NACT is recommended over PCS. 
 Histologic confirmation, preferably by core biopsy, should be con-
ducted in all patients prior to NACT. 
 A platinum/taxane doublet therapy is recommended for NACT; 
different regimens (containing a platinum agent) may be selected 
based on individual patient factors. 
 After ≤4 cycles of NACT, interval cytoreductive surgery should be 
performed in patients who had a response to NACT or stable dis-
ease. 
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7 Evidence 
A literature search was conducted on 15 January 2019 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “olaparib”, “lynparza”, “ovarian cancer”, “ovarian neo-
plasm”, “ovarian tumour”, “advanced”, “maintenance”, “newly diagnosed”, 
“first line” and “initial”. The manufacturer was also contacted and submit-
ted two references that both had already been identified by systematic litera-
ture search. A manual search identified 28 additional references (web docu-
ments and journal articles). 
Overall, 149 references were identified. Included in this reported is:  
 Primary analysis data from SOLO1, a multi-centre, randomised, 
double-blind, phase III trial assessing the efficacy and safety of 
olaparib maintenance therapy in patients with newly diagnosed ad-
vanced high-grade serous or endometrioid ovarian cancer, primary 
peritoneal cancer or fallopian tube cancer (or a combination there-
of) with a BRCA1/2 mutation, who had a CR or PR after platinum-
based chemotherapy. 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [17]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 6 (see Appendix). 
The external validity of the included trial was assessed using the EUnetHTA 
guideline on the applicability of evidence in the context of a relative effec-
tiveness assessment of pharmaceuticals, considering the following elements: 
population, intervention, comparator, outcomes and setting (see Table 5) 
[18]. 
To evaluate the magnitude of “clinically meaningful benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the ESMO (ESMO-MCBS) was used [19]. In addition, an 
adapted version (due to perceived limitations) of the ESMO-MCBS was ap-
plied [20]. Details of the magnitude of the clinically meaningful benefit as-
sessment are reported in Table 3. 
 
7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding the prevalence, incidence and amount of eli-
gible patients correct? 
systematic literature 
search in 5 databases:  
125 hits 
manual search: 28 
additional references 
 
overall: 153 references 
 
 
included: 1 study 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
applicability of study 
results 
magnitude of clinical 
benefit assessed based 
on ESMO-MCBS 
 
internal and external 
review  
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 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
7.2 Clinical efficacy and safety –  
phase III studies
The SOLO1 trial [5, 21, 22] is a multi-centre, randomised, double-blind, 
phase III trial conducted to evaluate the efficacy and safety of maintenance 
therapy with olaparib, a PARP inhibitor, in patients with newly diagnosed 
advanced ovarian cancer with a germline or somatic mutation in BRCA1, 
BRCA2, or both (BRCA1/2), who had a CR or PR after platinum-based 
chemotherapy. Between September 2013 and March 2015, a total of 391 pa-
tients from 15 countries underwent randomisation. After completion of plat-
inum-based chemotherapy, the patients were assigned in a 2:1 ratio to either 
the olaparib group (n=260) or to the placebo group (n=130, one patient 
withdrew before receiving the intervention). Patients who were eligible for 
the SOLO1 trial had to have newly diagnosed, histologically confirmed ad-
vanced FIGO stage III or IV high-grade serous or endometrioid ovarian can-
cer, primary peritoneal cancer, or fallopian tube cancer (or a combination 
thereof) and a deleterious or suspected deleterious germline or somatic 
BRCA1/2 mutation. Eligible patients had to have received platinum-based 
chemotherapy without bevacizumab and were having a clinical CR (no evi-
dence of disease on imaging after chemotherapy and a normal CA-125 level) 
or a clinical PR (a ≥30% decrease in tumour volume from the start to the 
end of chemotherapy or no evidence of disease on imaging after chemother-
apy, but a CA-125 level above the upper limit of the normal range). Since 
the SOLO1 trial is ongoing, primary and interim analysis data were present-
ed. 
Patients of both groups had a median age of 53 years; 76.9% of patients in 
the olaparib group and 80.2% of placebo group patients had an Eastern Co-
operative Oncology Group (ECOG) performance status of 0. In 84.6% of the 
olaparib group patients and in 86.3% of the placebo group patients, the pri-
mary tumour was located in the ovary. 73.5% of patients in the olaparib 
group had a BRCA1 mutation, as had 69.5% of placebo group patients. The 
majority of patients (81.9% in the olaparib group and 81.7% in the placebo 
group) showed a clinical CR after platinum-based chemotherapy. 76.2% of 
patients in the olaparib group and 80.9% of placebo group patients received 
six cycles of platinum-based chemotherapy. Detailed patient characteristics 
including inclusion and exclusion criteria can be found in Table 5. 
quality assurance 
method 
 
SOLO1: double-blind, 
placebo-controlled 
phase III trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
trial is ongoing; 
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Patients of the olaparib group received olaparib at a dose of 300 mg twice 
daily; patients of the placebo group received green film-coated tablets 
matching the olaparib tablets, administered in the same manner as olaparib. 
Study drug administration was continued until investigator-assessed objec-
tive disease progression on imaging, according to Response Evaluation Cri-
teria in Solid Tumours (RECIST, version 1.0). In patients who had no evi-
dence of disease at two years, the trial intervention was stopped, whereas pa-
tients who had a PR at two years were permitted to receive the study drug in 
a blinded manner.  
The primary endpoint of the SOLO1 trial was PFS, which was defined as the 
time from randomisation to objective disease progression on imaging or 
death from any cause. Secondary endpoints were second PFS (defined as the 
time from randomisation to second disease progression or death), OS, the 
time from randomisation to the first/second subsequent therapy or death, 
and health-related quality of life (HRQoL).  
The median duration of olaparib treatment among SOLO1 trial patients was 
24.6 months (ranging from 0.0–52.0 months), compared to 13.9 months 
(ranging from 0.2–45.6 months) in placebo group patients. The median du-
ration of follow-up was 40.7 months (olaparib group) and 41.2 months (pla-
cebo group). 47% of olaparib group patients and 27% of placebo group pa-
tients completed the trial intervention at two years (in accordance with the 
protocol). 10% (olaparib group) and 2% (placebo group) of patients contin-
ued to receive study treatment beyond two years. Of these, 13 patients still 
received olaparib and one patient received placebo at the time of data-cutoff 
for the primary analysis on 17 May, 2018. Clinical efficacy data of the SO-
LO1 trial is presented in Table 1, and adverse events (AEs) are listed in Ta-
ble 2. 
The SOLO1 trial is currently ongoing; the estimated study completion date 
is 6 June 2023 [23]. Due to the ongoing status of the SOLO1 trial, primary 
analysis data and interim analysis data (OS) was presented. 
 
7.2.1 Clinical efficacy 
D0001: What is the expected beneficial effect of olaparib on mortality? 
Data from an interim analysis of OS (data maturity, 21%
1
) showed that the 
Kaplan-Meier estimate of the rate of freedom from death at three years was 
84% in olaparib group patients, compared to 80% in placebo group patients; 
the hazard ratio (HR) was 0.95; 95% confidence interval (CI), 0.60–1.53, p-
value not reported [5]. 
 
 
 
                                                             
1
 According to the study protocol, an interim analysis for OS and second PFS will be 
performed at the time of the PFS analysis (approx. 100 OS events). A further analy-
sis of these two endpoints will be performed when the OS data are approx. 60% ma-
ture (approx. 206 events), which is anticipated to occur approx. 80 months after the 
first patient is enrolled in the study.  
olaparib tablets:  
300 mg twice daily vs. 
matching placebo 
tablets 
primary endpoint: PFS 
median duration of 
treatment (months): 
24.6 (olaparib) vs.  
13.9 (placebo) 
SOLO1 is ongoing until 
06/2023 
OS interim analysis data 
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D0006: How does olaparib affect progression (or recurrence) of ovarian can-
cer? 
PFS, as assessed by the investigators, was the primary endpoint of the SO-
LO1 trial; analysis was performed after 198 of the 391 patients had disease 
progression or had died; data maturity was 51%
2
. The Kaplan-Meier esti-
mate of the rate of freedom from disease progression and from death at three 
years (primary analysis data) was 60% in olaparib group patients, compared 
to 27% in placebo group patients (HR for disease progression or death was 
0.30, 95% CI 0.23–0.41, p<0.001). In patients of the placebo group, the me-
dian PFS from the end of chemotherapy was 13.8 months. The analysis of 
PFS as assessed by blinded independent central review (data maturity, 38%) 
showed a Kaplan-Meier estimate of the rate of freedom from disease pro-
gression and from death at three years of 69% in olaparib group patients 
versus 35% in placebo group patients (HR for disease progression or death 
was 0.28, 95% CI 0.20–0.39, p<0.001). To evaluate possible attrition bias, a 
sensitivity analysis of investigator-assessed PFS was performed, showing 
that the median PFS was 36.1 months longer in patients of the olaparib 
group than in patients of the placebo group (HR was 0.31, 95% CI 0.23–0.41, 
p<0.001) [5, 22]. 
Analysis of the second PFS (data maturity, 31%) showed a Kaplan-Meier es-
timate of the rate of freedom from second disease progression and from 
death at three years of 75% in olaparib group patients versus 60% in placebo 
group patients (HR for second disease progression or death was 0.50, 95% CI 
0.35–0.72, p<0.001). Among patients receiving placebo, the median second 
PFS was 41.9 months [5].  
 
D0005: How does olaparib affect symptoms and findings (severity, frequen-
cy) of ovarian cancer? 
In patients of the olaparib group, the median time to the first subsequent 
therapy or death was 51.8 months, compared to 15.1 months in patients of 
the placebo group (HR 0.30; 95% CI 0.22–0.40). The Kaplan-Meier estimate 
of the rate of freedom from the use of a second subsequent therapy and from 
death at three years was 74% in olaparib group patients versus 56% in pla-
cebo group patients: HR for the use of a second subsequent therapy or death 
was 0.45; 95% CI 0.32–0.63. The median time to the second subsequent ther-
apy or death was 40.7 months in patients of the placebo group. Based on 
Kaplan-Meier estimates, the rate of freedom from disease progression and 
death among patients receiving olaparib compared to patient receiving pla-
cebo was 88% and 51% at one years, 74% and 35% at two years, 60% and 
27% at three years, and 53% and 11% at four years, respectively [5].  
 
                                                             
2
 It was determined that 206 primary end-point events (disease progression or death) 
would provide the trial with 90% power, at a two-sided significance level of 0.05, to 
show a significant difference in PFS between the olaparib group and the placebo 
group, with a corresponding HR for disease progression or death of 0.62 (assuming 
a median PFS of 13 months in the placebo group). Due to the fact that the rate of 
primary end-point events was lower than projected, the protocol was amended such 
that the primary analysis of PFS was to be performed when approx. 196 events had 
occurred (data maturity, approximately 50%) or when the last patient to undergo 
randomisation had done so at least 3 years earlier, whichever came first. 
PFS prolonged in 
patients of olaparib 
group 
 
 
70% lower risk of 
disease progression or 
death with olaparib 
than with placebo 
 
 
sensitivity analysis 
performed 
higher rate of 2nd PFS in 
olaparib group patients 
than in placebo group 
patients 
time to 1st and 2nd 
subsequent therapy and 
death at 3 years 
prolonged with olaparib 
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D0011: What is the effect of olaparib on patients̕ body functions? 
Patients of the SOLO1 trial who received olaparib had a higher rate of dysp-
noea of any grade (15%), as compared to patients of the placebo group (5%). 
There was no grade 3/4 dyspnoea reported in either group. Pneumonitis or 
interstitial lung disease occurred in 2% of olaparib group patients and in 
none of the placebo group patients [5]. 
 
D0012: What is the effect of olaparib on generic health-related quality of 
life?  
D0013: What is the effect of olaparib on disease-specific quality of life? 
In patients of the SOLO1 trial, the HRQoL was evaluated by the use of the 
Trial Outcome Index (TOI) score on the Functional Assessment of Cancer 
Therapy-Ovarian Cancer (FACT-O) questionnaire. TOI scores ranged from 
0 to 100; higher scores indicate better HRQoL, and a difference of 10 points 
indicates a clinically meaningful difference [5, 22].  
At baseline, the mean TOI score was 73.6 in patients of the olaparib group 
and 75.0 in patients of the placebo group. In the olaparib group, the score 
remained stable from baseline to two years (adjusted mean change of 0.30 
points, 95% CI, -0.72–1.32). Among patients of the placebo group, a change 
of 3.30 points (95% CI, 1.84–4.76) could have been observed from baseline to 
two years. The estimated between-group difference in change was -3.00 
points (95% CI, -4.78 to -1.22), and not considered to be clinically meaning-
ful [5]. 
 
 
 
 
 
 
  
higher rate of dyspnoea, 
pneumonitis/interstitial 
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difference in change of 
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Table 1: Efficacy results of SOLO1 trial [5, 22] 
Descriptive sta-
tistics and esti-
mate variability 
Treatment group Olaparib Placebo 
Number of patients 260 130 
Rate of freedom from disease progression and 
death at 3 years (investigator-assessed), % 
60 27 
Median PFS from the end of chemotherapy, 
months 
- 13.8 
Rate of freedom from disease progression and 
death at 3 years (assessed by blinded independ-
ent review), % 
69 35 
Rate of freedom from disease progression and 
death (investigator-assessed), % 
   at 1 year 
   at 2 years 
   at 3 years 
   at 4 years 
 
 
88 
74 
60 
53 
 
 
51 
35 
27 
11 
Rate of freedom from second disease progression 
and death at 3 years, % 
75 60 
Median second PFS, months - 41.9 
Rate of freedom from death (OS) at 3 years, % 84 80 
Median time to first subsequent therapy or 
death, months 51.8 15.1 
Rate of freedom from the use of a second subse-
quent therapy and death at 3 years, % 
74 56 
Median time to second subsequent therapy or 
death, months 
- 40.7 
TOI score change from baseline to 2 years, points 0.30 3.30 
Effect estimate 
per comparison 
 
Comparison groups Olaparib vs. placebo 
Rate of freedom from disease progression and 
death at 3 years (investigator-assessed) 
HR for disease progression or death 0.30 
95% CI 0.23–0.41 
p-value <0.001 
Rate of freedom from disease progression and 
death at 3 years (assessed by blinded independ-
ent review) 
HR for disease progression or death 0.28 
95% CI 0.20–0.39 
p-value <0.001 
Rate of freedom from second disease progression 
and death at 3 years 
HR for second disease progression 
or death 
0.50 
95% CI 0.35–0.72 
p-value <0.001 
Rate of the freedom from death (OS) at 3 years 
HR for death 0.95 
95% CI 0.60–1.53 
p-value NR 
Median time to first subsequent therapy or death 
HR 0.30 
95% CI 0.22–0.40 
p-value NR 
Use of a second subsequent therapy or death 
HR 0.45 
95% CI 0.32–0.63 
p-value NR 
Between-group difference of TOI score from 
baseline to 2 years 
HR NR 
95% CI -4.78 to -1.22 
p-value NR 
Abbreviations: CI = confidence interval, HR = hazard ratio, NR =not reported, OS = overall survival, PFS = progression-free survival, TOI = Trial Outcome 
Index 
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7.2.2 Safety 
 
C0008: How safe is olaparib in relation to the comparator(s)? 
Adverse events (AEs) of any grade that occurred during the trial interven-
tion or up to 30 days after discontinuation of the intervention were reported 
in 98% of olaparib group patients and 92% of placebo group patients. Most 
common AEs of any grade among olaparib group patients were nausea, fa-
tigue or asthenia, vomiting, anaemia and diarrhoea. Among placebo group 
patients, nausea, fatigue or asthenia occurred most frequently.  
AEs of grade 3 or 4 occurred in 39% of olaparib group patients and 18% of 
placebo group patients; the most common were anaemia (22%) and neutro-
penia (9%) in patients receiving olaparib, and neutropenia (5%) in patients 
receiving placebo. 
Serious AEs occurred in 21% of patients receiving olaparib and 12% of pa-
tients who received placebo. The most common serious, treatment-emergent 
AEs in the olaparib group were anaemia (6.5%) and urinary tract infection 
(1.2%), which occurred in no patients of the placebo group. No AEs that oc-
curred during the study intervention (or up to 30 days after discontinuation) 
led to death. 
Among patients of the olaparib group, AEs led to discontinuation of the in-
tervention in 12% of patients, to dose reduction in 28% of patients, and to 
dose interruption in 52% of patients. In the placebo group, AEs led to dis-
continuation of the intervention in 2% of patients, to dose reduction in 3% 
of patients, and to dose interruption in 17% of patients. The most common 
AEs leading to discontinuation in patients receiving olaparib were nausea 
and anaemia (2.3% each). Three patients (1%) of the olaparib group were af-
fected by acute myeloid leukaemia (AML), occurring more than 30 days af-
ter the end of study treatment, and in none of patients of the placebo group. 
New primary cancers were reported in 2% of patients in either group. In pa-
tients receiving olaparib, pneumonitis and interstitial lung disease were re-
ported in 2% of them [5, 22]. 
 
C0002: Are the harms related to dosage or frequency of applying olaparib? 
The mode of administration and dosing of olaparib used in the SOLO1 trial 
is consistent with the FDA-approved license [8]. AEs occurring in SOLO1 
trial participants were usually managed by dose interruption or dose reduc-
tion [5]. According to the FDA label information, the recommended dose 
reduction is 250 mg (one 150 mg tablet and one 100 mg tablet) taken twice 
daily, for a total daily dose of 500 mg [8].  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of olaparib? 
According to FDA label information, the following warnings and precau-
tions are listed [8]: 
 Myelodysplastic syndrome (MDS)/AML: The incidence of 
MDS and AML in patients who received olaparib mono-
therapy in clinical trials (including long-term follow-up) 
most common AEs of 
any grade in olaparib 
group: nausea, fatigue, 
asthenia, vomiting, 
anaemia, diarrhoea  
AEs grade 3/4:  
in 39% (olaparib) vs. 
18% (placebo) 
serious AEs  
in 21% (olaparib) vs. 
12% (placebo) 
AEs led to 
discontinuation  
in 12% (olaparib) vs. 2% 
(placebo) of patients 
 
1% of olaparib group 
patients affected by 
AML 
SOLO1: AEs usually 
managed by dose 
interruption/dose 
reduction rather than 
discontinuation 
warnings and 
precautions: 
MDS, AML, 
pneumonitis, embryo-
foetal toxicity 
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was <1.5% with a predominantly fatal outcome, and addi-
tional cases were reported in patients treated with olaparib 
in combination studies and post-marketing reports. All of 
these patients had received previous chemotherapy. 
Olaparib should not be administered until patients have 
recovered from haematological toxicity caused by previous 
chemotherapy. Complete blood count should be monitored 
for cytopenia. In the case of prolonged haematological tox-
icities, olaparib treatment should be interrupted and blood 
counts should be monitored weekly until recovery. If the 
levels have not recovered (to grade ≤1) after four weeks, 
further investigation should be performed; if MDS or 
AML is confirmed, olaparib should be discontinued. 
 Pneumonitis: If new or worsening respiratory symptoms 
(e.g., dyspnoea, cough, fever or radiological abnormality) 
occur in patients treated with olaparib, the intervention 
should be interrupted for further investigation. If pneu-
monitis is confirmed, olaparib treatment should be discon-
tinued and the patient needs to be treated appropriately. 
 Embryo-foetal toxicity: Since olaparib can cause foetal 
harm, patients should be advised to use effective contra-
ception during treatment and for six months following the 
last dose of olaparib. 
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Table 2: Most frequent adverse events [5] 
 
Adverse event (according  
to NCI-CTCAE version 4.0) 
 
Olaparib (n = 260) Placebo (n = 130) 
 Any grade  
n (%) 
Grade 3 or 4 
n (%) 
Any grade 
n (%) 
Grade 3 or 4 
n (%) 
Any 256 (98) 102 (39) 120 (92) 24 (18) 
Nausea 201 (77) 2 (1) 49 (38) 0 (0) 
Fatigue or asthenia 165 (63) 10 (4) 54 (42) 2 (2) 
Vomiting 104 (40) 1 (<1) 19 (15) 1 (1) 
Anaemia 101 (39) 56 (22) 13 (10) 2 (2) 
Diarrhoea 89 (34) 8 (3) 32 (25) 0 (0) 
Constipation 72 (28) 0 (0) 25 (19) 0 (0) 
Dysgeusia 68 (26) 0 (0) 5 (4) 0 (0) 
Arthralgia 66 (25) 0 (0) 35 (27) 0 (0) 
Abdominal pain 64 (25) 4 (2) 25 (19) 1 (1) 
Neutropenia 60 (23) 22 (9) 15 (12) 6 (5) 
Headache 59 (23) 1 (<1) 31 (24) 3 (2) 
Dizziness 51 (20) 0 (0) 20 (15) 1 (<1) 
Decreased appetite 51 (20) 0 (0) 13 (10) 0 (0) 
Upper abdominal pain 46 (18) 0 (0) 17 (13) 0 (0) 
Dyspepsia 43 (17) 0 (0) 16 (12) 0 (0) 
Cough 42 (16) 0 (0) 28 (22) 0 (0) 
Back pain 40 (15) 0 (0) 16 (12) 0 (0) 
Dyspnoea 39 (15) 0 (0) 7 (5) 0 (0) 
Thrombocytopenia 29 (11) 2 (1) 5 (4) 2 (2) 
Led to discontinuation of 
intervention 30 (12) NA 3 (2) NA 
Led to dose reduction 74 (28) NA 4 (3) NA 
Led to dose interruption 135 (52) NA 22 (17) NA 
Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events, n = Number, NA = not available, NCI = Na-
tional Cancer Institute 
 
 
7.3 Clinical effectiveness and safety –  
further studies 
Currently, the SOLO1 trial is the only trial investigating the role of olaparib 
in patients with newly diagnosed advanced ovarian cancer and a BRCA1/2 
mutation, who had a CR or PR after platinum-based chemotherapy. Ongo-
ing trials assessing olaparib in different settings/combinations are listed in 
Chapter 9. 
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8 Estimated costs 
A0021: What is the reimbursement status of olaparib? 
In Austria, Lynparza
® 
is available as tablets (100 and 150 mg) and capsules 
(50 mg). The costs for 112 Lynparza
®
 tablets (150 mg) are € 5,059.29 (ex-
factory price [4]. 
Patients of the SOLO-1 trial, who were assigned to the olaparib group, re-
ceived 300 mg of olaparib twice daily. Based on this dosing regimen, 28 days 
of olaparib treatment would cost € 5,059.29. The median duration of the trial 
intervention among patients of the olaparib group was 24.6 months, result-
ing in costs of € 124,458.53. 
In addition, costs are incurred for the BRCA mutation status test and the 
platinum-based chemotherapy, which is administered prior to olaparib 
maintenance treatment. 
 
 
9 Ongoing research 
In January 2019, a search in the databases www.clinicaltrials.gov and 
www.clinicaltrialsregister was conducted. The SOLO1 trial (NCT01844986) 
is currently ongoing with an estimated study completion date in June 2023. 
Two trials evaluating the efficacy and safety of olaparib administered in pa-
tients with newly diagnosed advanced ovarian cancer were identified: 
 NCT02477644 (EudraCT Number: 2014-004027-52): PAOLA-1 is a 
randomised, double-blind, phase III trial of olaparib versus placebo 
in patients with advanced FIGO stage IIIB-IV high grade serous or 
endometrioid ovarian, fallopian tube or peritoneal cancer treated 
with standard first-line treatment, combining platinum-taxane 
chemotherapy and bevacizumab concurrent with chemotherapy 
and maintenance. Estimated study completion date is June 2022. 
 NCT03737643 (EudraCT Number: 2017-004632-11): DUO-O is a 
randomised, double-blind, multi-centre study to evaluate the effi-
cacy and safety of durvalumab in combination with standard of care 
platinum-based chemotherapy and bevacizumab followed by 
maintenance durvalumab and bevacizumab or durvalumab, bevaci-
zumab and olaparib in patients with newly diagnosed advanced 
ovarian cancer. Estimated study completion date is July 2025. 
The OLALA study (NCT02489058, EudraCT Number: 2017-002808-28) is 
an observational and sample collecting study of long-term responders on 
olaparib in solid tumours, aiming to elucidate how olaparib works and to 
better identify patients who may benefit from this therapy. 
There are several trials assessing olaparib in patients with previously treated 
and relapsed disease, such as the ICON9 trial (NCT03278717), the OPIN-
ION trial (NCT03402841) or the OReO trial (NCT03106987). Further trials 
are aiming to investigate the efficacy and safety of olaparib in different dis-
112 Lynparza® tablets = 
€  5,059.29 
€  5,059.29 for 1 month 
of olaparib treatment 
€ 124,458.53 for 2 years 
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eases, including breast cancer, pancreatic cancer, castration-resistant pros-
tate cancer or advanced gastric cancer. 
 
 
10 Discussion 
In December 2018, the FDA approved olaparib (Lynparza
®
) for the first-line 
maintenance treatment of adult patients with deleterious or suspected dele-
terious gBRCAm or sBRCAm advanced epithelial ovarian, fallopian tube or 
primary peritoneal cancer, who are in CR or PR to first-line platinum-based 
chemotherapy [7]. To date, olaparib has not yet been approved by the EMA 
for the assessed indication [6]. 
The SOLO1 trial [5, 21, 22] evaluated the efficacy and safety of olaparib 
first-line maintenance therapy in patients with newly diagnosed advanced 
ovarian cancer, primary peritoneal cancer or fallopian tube cancer and a 
BRCA1/2 mutation, who had a CR or PR after platinum-based chemothera-
py. Investigator-assessed analysis showed that the Kaplan-Meier estimate of 
the rate of freedom from disease progression and from death at three years 
was 60% in the olaparib group versus 27% in the placebo group (HR for dis-
ease progression or death was 0.30). According to the analysis assessed by 
blinded independent central review, the Kaplan-Meier estimate of the rate 
of freedom from disease progression and from death at three years was 69% 
in the olaparib group versus 35% in the placebo group. A sensitivity analysis 
of investigator-assessed PFS showed that the median PFS was 36.1 months 
longer in patients of the olaparib group than in patients of the placebo group 
(HR was 0.31). The Kaplan-Meier estimate of the rate of freedom from sec-
ond disease progression and from death at three years was higher among pa-
tients of the olaparib group (75%) than among patients of the placebo group 
(60%). An interim analysis of OS data showed a Kaplan-Meier estimate of 
the rate of freedom from death at three years of 84% (olaparib group) versus 
80% (placebo group); HR for death was 0.95. The median time to the first 
subsequent therapy or death was longer in olaparib group patients (51.8 
months) than in placebo group patients (15.1 months). The estimated be-
tween-group difference in change of TOI score was -3.00 points, and thus 
considered not to be clinically meaningful. 
Since the SOLO1 trial is ongoing until June 2023, no final data analysis is 
available; the presented results are primary and interim analysis results. 
Due to the fact that the OS data are currently immature and the estimated 
between-group difference in change of HRQoL was not clinically meaning-
ful, the clinical benefit of olaparib maintenance could not be confirmed. 
This is especially important, since the confidence intervals of the hazard ra-
tio of death (HR 0.95, 95% CI, 0.60–1.53) indicate that olaparib offers no 
survival improvement. However, among SOLO1 trial patients, olaparib 
maintenance therapy provided a benefit in PFS, second PFS, and the medi-
an time to the first (and second) subsequent therapy or death. This is rele-
vant with regard to the fact that the majority of patients—despite optimal 
upfront surgery and administration of paclitaxel/carboplatin chemothera-
py—have a relapse within the first three years [10]. Nevertheless, since new-
ly diagnosed advanced ovarian cancer can potentially be cured [24], the final 
analysis of OS data and the assessment of the long-term benefit of olaparib 
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was 70% lower with 
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needed 
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maintenance therapy are substantial. It should be noted that patients who 
had a PR at two years were permitted to receive olaparib in a blinded man-
ner; hence, the validity of SOLO1 long-term data may be affected by this 
cross-over approach. 
As mentioned above, the primary analysis of HRQoL data showed no clini-
cally meaningful between-group difference between patients of the olaparib 
group and patients of the placebo group [5]. Since HRQoL is a clinically 
important aspect for patients, final analysis data are of major importance. 
Data from SOLO2 trial [25], a phase 3 trial evaluating olaparib maintenance 
therapy in platinum-sensitive, relapsed ovarian cancer patients with a 
BRCA1/2 mutation, who received at least two lines of previous chemothera-
py, showed that olaparib led to a significant improvement in PFS without 
significant detrimental effect on HRQoL. Furthermore, the delay of progres-
sion was associated with a longer duration of “good quality of life”. Leder-
mann et al. [26] assessed that maintenance treatment with olaparib was well-
tolerated and had no adverse impact on HRQoL in a phase II study of pa-
tients with platinum-sensitive relapsed serous ovarian cancer who had re-
sponded (CR or PR) to their most recent platinum-based therapy. Final 
analysis of SOLO1 HRQoL data might confirm these findings. 
To date, the SOLO1 trial is the only trial investigating the role of olaparib in 
patients with newly diagnosed advanced ovarian cancer and a BRCA1/2 mu-
tation, who had a CR or PR after platinum-based chemotherapy. Available 
data from different trials refer to olaparib maintenance therapy in patients 
with relapsed disease, e.g., the SOLO2 trial [27]. In the ARIEL3 trial [28], 
rucaparib, a different PARP inhibitor, versus placebo was assessed in pa-
tients with high-grade, platinum-sensitive, recurrent ovarian carcinoma af-
ter response to second-line or later platinum-based chemotherapy. Further 
investigation may give information about the role of rucaparib as mainte-
nance therapy in patients with newly diagnosed ovarian cancer. Further-
more, a direct comparison of rucaparib and olaparib may help find the op-
timal treatment for this patient population. The same applies to niraparib, a 
PARP inhibitor investigated versus placebo as maintenance treatment for 
patients with platinum-sensitive, recurrent ovarian cancer who had received 
at least two platinum-based therapies in the course of the phase III ENGOT-
OV16/NOVA trial [29]. In this regard, the results of OVARIO [30], a phase 
II, single-arm, open-label study to assess the safety and efficacy of niraparib 
combined with bevacizumab as maintenance treatment in patients with new-
ly diagnosed advanced ovarian cancer, fallopian tube cancer, or primary per-
itoneal cancer following front-line platinum-based chemotherapy with 
bevacizumab, will be of interest. 
AEs of grade 3 or 4 occurred in 39% of olaparib group patients and 18% of 
placebo group patients; serious AEs occurred in 21% of patients receiving 
olaparib and 12% of patients who received placebo. No AEs that occurred 
during the study intervention (or up to 30 days after discontinuation) led to 
death. AEs led to discontinuation of the intervention in 12% (olaparib 
group) and 2% (placebo group) of patients. Three patients (1%) of the 
olaparib group were affected by acute myeloid leukaemia (AML), occurring 
more than 30 days after the end of study treatment. Pneumonitis and inter-
stitial lung disease were reported in 2% of patients of the olaparib group and 
in none of placebo group patients. It can be noted that most AEs in olaparib 
group patients could have been managed by dose reduction (28%) and dose 
interruption (52%), rather than study drug discontinuation (12%) [5].  
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placebo group 
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patients with newly 
diagnosed ovarian 
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Given the non-curative setting of olaparib and the statistically significant 
primary endpoint PFS, we applied form 2b of the ESMO-MCBS in order to 
assess whether olaparib satisfies the criteria for a “meaningful clinical bene-
fit” (score 4 or 5) [19]. However, since the median PFS and OS were not 
available for the olaparib group, no score calculations could be applied. 
The SOLO1 trial was conducted as a double-blind study. Adequate genera-
tion of the randomisation sequence and adequate allocation concealment 
were described in the protocol; the reasons for treatment discontinuation 
were reported. However, no median PFS data were available and, additional-
ly, some other aspects that may affect the risk of bias were identified: the tri-
al was designed by the first and last authors in collaboration with the manu-
facturer and the Gynecologic Oncology Group. The manufacturer was re-
sponsible for overseeing the collection, analysis, and interpretation of the 
data. Hence, the risk of bias is considered to be high. Regarding the applica-
bility of evidence, it is notable that the trial population was highly selected 
and the median age of participants was approximately ten years lower than 
the median age at diagnosis of ovarian cancer usually is. Moreover, almost 
80% of the olaparib group patients had an ECOG performance status of 0, 
meaning that the women were able to carry on normal activity. Due to the 
fact that final analysis data are lacking and OS data at the time of interim 
analysis were immature, the applicability of results is limited. 
The costs for 28 days of olaparib treatment are € 5,059.29 (ex-factory price 
[4]. The median duration of olaparib administration among patients of the 
SOLO1 trial was 24.6 months, resulting in costs of € 124,458.53. In addition, 
costs are incurred for the BRCA mutation status test and the platinum-
based chemotherapy which is administered prior to olaparib maintenance 
treatment. 
SOLO1 trial results showed a benefit with olaparib first-line maintenance 
therapy in the delay of disease progression in patients with newly diagnosed 
ovarian cancer and BRCA1/2 mutation. However, the trial is currently ongo-
ing, the presented data are the primary analysis data, and interim OS data 
are immature. HRQoL data also derive from the primary analysis and the 
detected between-group difference was not considered to be clinically mean-
ingful. Final analysis data from the SOLO1 trial are pending and may con-
firm the clinical benefit of first-line olaparib maintenance therapy. Further 
investigation of olaparib first-line maintenance therapy in phase III trials, 
long-term data, as well as a direct comparison of olaparib with different 
PARP inhibitors, are warranted to determine the optimal treatment for this 
patient population.  
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [19, 20] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapt-ed 
ESMO-
MCBS 
Olaparib Ovarian 
cancer 
NC PFS - - - - - - - - - NA3 
Original 
ESMO-
MCBS 
Olaparib Ovarian cancer NC PFS - - - - - - - - - NA3 
Abbreviations: AJ = Adjustments, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, NA = not applicable, PE = primary endpoint, PFS = 
progression-free survival, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: By the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI).We thus decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
 
 
                                                             
3
 An ESMO-MCBS score cannot be assessed, since none of the available study endpoints was applicable to evaluate the MCBS. 
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12 Appendix  
Table 4: Administration and dosing of olaparib (Lynparza
®
) [2, 21] 
 Technology Comparator 
Administration mode 
Lynparza® is for oral use; the tablets should be swallowed whole 
and not chewed, crushed, dissolved or divided. Lynparza® tablets 
may be taken without regard to meals. 
Placebo will be available as 
green film-coated tablets 
matching the olaparib tab-
lets.  
Description of packaging 
Lynparza® 100 mg tablets are yellow to dark yellow, oval, bi-
convex, film-coated tablets, marked with “OP100” on one side and 
plain on the other. 
Lynparza® 150 mg tablets are green to green/grey, oval, bi-convex, 
film-coated tablets, marked with “OP150” on one side and plain on 
the other. 
- 
Total volume contained in packaging for sale 
Lynparza® is supplied in packs containing 56 film-coated tablets (7 
blisters of 8 tablets each), or multipacks containing 112 (2 packs of 
56) film-coated tablets. 
- 
Dosing 
The recommended dose of Lynparza® is 300 mg (two 150 mg tab-
lets) taken twice daily, equivalent to a total daily dose of 600 mg. 
Placebo tablets should be 
taken as per instructions for 
olaparib tablets. 
Median treatment duration 
SOLO1 trial: The median duration of the trial intervention in the 
olaparib group was 24.6 months (ranging from 0.0 to 52.0). 
SOLO1 trial: The median du-
ration in the placebo group 
was 13.9 months (ranging 
from 0.2 to 45.6). 
Contraindications 
 Hypersensitivity to the active substance or to any of the ex-
cipients (tablet core: copovidone, silica, colloidal anhydrous, 
mannitol, sodium stearyl fumarate/tablet coating: hypro-
mellose, macrogol 400, titanium dioxide [E171], iron oxide 
yellow [E172], iron oxide black [E172, 150 mg tablets only]) 
 Breast-feeding during treatment and for 1 month after the 
last dose. Olaparib should not be used during pregnancy and 
in women of childbearing potential not using reliable contra-
ception during therapy and for 1 month after receiving the 
last dose of olaparib. 
- 
Drug interactions 
Clinical studies of olaparib in combination with other anticancer 
medicinal products, including DNA-damaging agents, indicate a po-
tentiation and prolongation of myelosuppressive toxicity. The rec-
ommended Lynparza® monotherapy dose is not suitable for combi-
nation with myelosuppressive anticancer medicinal products. 
Combination of olaparib with vaccines or immunosuppressant 
agents has not been studied. Therefore, caution should be taken if 
these medicinal products are co-administered with olaparib and pa-
tients should be closely monitored. 
Known strong (e.g., itraconazole, telithromycin, clarithromycin, 
protease inhibitors boosted with ritonavir or cobicistat, boceprevir, 
telaprevir) or moderate (e.g., erythromycin, diltiazem, fluconazole, 
verapamil) inhibitors of CYP3A are not recommended with olaparib.  
It is also not recommended to consume grapefruit juice while on 
olaparib therapy, as it is a CYP3A inhibitor. 
Known strong inducers of CYP3A (e.g., phenytoin, rifampicin, 
rifapentine, carbamazepine, nevirapine, phenobarbital, and St 
John’s Wort) are not recommended with olaparib, as it is possible 
that the efficacy of olaparib could be substantially reduced. The 
magnitude of the effect of moderate to strong inducers (e.g., efavi-
renz, rifabutin) on olaparib exposure is not established; therefore, 
the co-administration of olaparib with these medicinal products is 
also not recommended. 
Caution should be exercised when sensitive CYP3A substrates or 
substrates with a narrow therapeutic margin (e.g., simvastatin, cis-
apride, cyclosporine, ergot alkaloids, fentanyl, pimozide, sirolimus, 
tacrolimus and quetiapine) are combined with olaparib. Appropri-
ate clinical monitoring is recommended for patients receiving 
CYP3A substrates with a narrow therapeutic margin concomitantly 
with olaparib. 
The potential for olaparib to induce CYP2C9, CYP2C19 and P-gp can 
also not be excluded. Therefore, olaparib upon co-administration 
- 
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may reduce the exposure to substrates of these metabolic enzymes 
and transport protein. The efficacy of some hormonal contracep-
tives may be reduced if co-administered with olaparib.  
Olaparib may cause clinically relevant drug interactions with sub-
strates of P-gp (e.g., simvastatin, pravastatin, dabigatran, digoxin 
and colchicine). Appropriate clinical monitoring is recommended. 
It cannot be excluded that olaparib may increase the exposure to 
substrates of BCRP (e.g., methotrexate, rosuvastatin), OATP1B1 
(e.g., bosentan, glibenclamide, repaglinide, statins and valsartan), 
OCT1 (e.g., metformin), OCT2 (e.g., serum creatinine), OAT3 (e.g., 
furosemide and methotrexate), MATE1 (e.g., metformin) and MA-
TE2K (e.g., metformin). In particular, caution should be exercised if 
olaparib is administered in combination with any statin. 
Tamoxifen decreased exposure to olaparib by 27%. The clinical rel-
evance of this effect is unknown.  
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Table 5: Characteristics of SOLO1 trial  
Title: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer [5, 21, 22] 
Study identifier NCT01844986, EudraCT Number: 2013-001551-13 
Design International, randomised, double-blind, placebo-controlled phase III trial 
Duration of main phase: Randomisation: from September 3, 2013 to March 6, 2015 
 Time of data cut-off for the primary analysis: May 17, 2018 
 Median follow-up:41 months 
Hypothesis Superiority 
Funding Astra Zeneca and Merck 
Treatments groups 
 
Intervention (n = 260) 
Patients received olaparib tablets (300 mg) twice daily 
until investigator-assessed objective disease progression 
on imaging (according to modified RECIST, version 1.1), 
provided that the patient was having a benefit and did not 
meet any discontinuation criteria. Patients who had no ev-
idence of disease at 2 years stopped receiving the trial in-
tervention, but patients who had a PR at 2 years were 
permitted to continue receiving the trial intervention in a 
blinded manner. 
Control (n = 130) Patients received placebo tablets (matching the olaparib tablets). 
Endpoints and definitions 
 
Progression-free sur-
vival (primary end-
point) 
 
PFS Defined as the time from randomisation to objective dis-
ease progression on imaging (according to modified RE-
CIST, version 1.1) or death from any cause 
Second progression-
free survival 
PFS2 The time from randomisation to second disease progres-
sion or death 
Overall survival OS 
Defined as the time from the date of randomisation until 
death due to any cause 
Time from randomi-
sation to the first 
subsequent therapy 
or death 
- - 
 Time from randomi-
sation to the second 
subsequent therapy 
or death 
- - 
Health-related quality 
of life HRQoL Assessed by the TOI of the FACT-O 
Database lock NR 
Results and analysis  
Olaparib (Lynparza
®
) as first-line maintenance therapy in patients with newly diagnosed advanced ovar-
ian cancer 
LBI-HTA | 2019 35 
Title: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer [5, 21, 22] 
Study identifier NCT01844986, EudraCT Number: 2013-001551-13 
Analysis description Primary analysis 
It was determined that 206 primary endpoint events (disease progression or death) would provide 
the trial with 90% power, at a two-sided significance level of 0.05, to show a significant difference 
in PFS between the olaparib group and the placebo group, with a corresponding HR for disease 
progression or death of 0.62 (assuming a median PFS of 13 months in the placebo group). Because 
the rate of primary endpoint events was lower than projected, the protocol was amended such that 
the primary analysis of PFS was to be performed when approximately 196 events had occurred (da-
ta maturity, approximately 50%) or when the last patient to undergo randomisation had done so 
at least 3 years earlier, whichever came first. Data on efficacy and HRQoL were summarised and 
analysed in the ITT population (all patients who underwent randomisation, regardless of the inter-
vention that they actually received). Data on safety were summarised in the safety population (all 
patients who received ≥ 1 dose of the trial intervention). A multiple-testing procedure was used to 
control the type I error rate, with a test for PFS to be performed first, a test for second PFS to be 
performed if the null hypothesis for PFS were rejected, and a test for OS to be performed if the re-
sults for PFS and PFS2 were significant. The analyses of time to the first subsequent therapy and 
time to the second subsequent therapy were not adjusted for multiple comparisons. 
To describe the potential benefit of olaparib, tests for time to the first subsequent therapy, time to 
the second subsequent therapy, and change from baseline in the TOI score were performed at a 
two-sided significance level of 0.05. The analysis of PFS was performed with a stratified log-rank 
test, with calculation of a hazard ratio, an accompanying 95% confidence interval, and a P value. 
Analyses of PFS2, OS, time to the first subsequent therapy, and time to the second subsequent 
therapy were performed with a method similar to that used for the analysis of PFS. The analysis of 
change from baseline in the TOI score was performed with a mixed-effects model for repeated 
measures. 
Analysis population   
Inclusion 
 Patients must be aged ≥18 years 
 Female patients with newly diagnosed, histologically confirmed, ad-
vanced (FIGO stage III-IV) BRCA mutated high-grade serous or high 
grade endometrioid (based on local histopathological findings) ovar-
ian cancer, primary peritoneal cancer and/or fallopian tube cancer 
who have completed first-line, platinum-based chemotherapy (IV or 
intraperitoneal) 
 Stage III patients must have had one attempt at optimal debulking 
surgery; stage IV patients must have had either a biopsy and/or up-
front or interval debulking surgery. 
 Deleterious or suspected deleterious germline or somatic BRCA1/2 
mutation, as determined by local or central testing, with the use of 
the BRACAnalysis test (Myriad) or, in China, with the use of a 
BRCA1/2 genetic testing assay (BGI) 
 Patients had received platinum-based chemotherapy without bevaci-
zumab and were having a complete clinical response (no evidence of 
disease on imaging after chemotherapy and a normal CA-125 level) or 
a partial clinical response (a ≥30% decrease in tumour volume from 
the start to the end of chemotherapy or no evidence of disease on 
imaging after chemotherapy but a CA-125 level above the upper limit 
of the normal range. 
 Patients must have normal organ and bone marrow function. 
 ECOG performance status 0-1 
 Life-expectancy of ≥16 weeks 
 Postmenopausal or evidence of non-childbearing status for women 
of childbearing potential 
 Formalin-fixed, paraffin-embedded tumour sample from the primary 
cancer must be available for central testing. 
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Exclusion 
 BRCA1 and/or BRCA2 mutations that are considered to be non-
detrimental 
 Patients with early-stage disease (FIGO stage I,IIA, IIB, or IIC) 
 Stable disease or progressive disease on the post-treatment scan, or 
clinical evidence of progression at the end of the patient’s first-line 
chemotherapy treatment 
 Patients where more than 1 debulking surgery has been performed 
before randomisation to the study. Eligible patients are those who, 
at the time of diagnosis, are deemed to be unresectable and undergo 
only a biopsy or oophorectomy, but then go on to receive chemo-
therapy and interval debulking surgery. 
 Patients who have previously been diagnosed and treated for earlier 
stage ovarian, fallopian tube or primary peritoneal cancer 
 Patients who have previously received chemotherapy for any ab-
dominal or pelvic tumour, including treatment for prior diagnosis at 
an earlier stage for their ovarian, fallopian tube or primary peritone-
al cancer 
 Patients with synchronous primary endometrial cancer unless both 
of the following criteria are met: 
o stage <2 
o less than 60 years old at the time of diagnosis of endometrial 
cancer with stage IA or IB grade 1 or 2, or stage IA grade 3 en-
dometrioid adenocarcinoma OR ≥60 years old at the time of 
diagnosis of endometrial cancer with stage IA grade 1 or 2 en-
dometrioid adenocarcinoma. 
 Patients who have had a drainage of their ascites during the final 
two cycles of their last chemotherapy regimen prior to enrolment in 
the study 
 Any previous treatment with a PARP inhibitor, including olaparib 
 Other malignancy within the last 5 years (for exceptions, see sup-
plementary appendix) 
 Resting ECG with a corrected QT interval >470 msec on two or more 
time points within a 24-hour period or family history of long QT 
syndrome 
 Patients receiving any systemic chemotherapy or radiotherapy (ex-
cept for palliative reasons) within 3 weeks prior to study treatment 
(or a longer period depending on the defined characteristics of the 
agents used) 
 Concomitant use of known potent cytochrome P450 inhibitors 
 Persistent toxicities (CTCAE grade ≥2) caused by previous cancer 
therapy, excluding alopecia 
 Patients with myelodysplastic syndrome/acute myeloid leukaemia 
 Patients with symptomatic, uncontrolled brain metastases 
 Major surgery within 2 weeks of starting study treatment, and pa-
tients must have recovered from any effects of any major surgery 
 Patients considered a poor medical risk due to a serious, uncon-
trolled medical disorder, non-malignant systemic disease or active, 
uncontrolled infection 
 Patients unable to swallow orally administered medication, and pa-
tients with gastrointestinal disorders likely to interfere with absorp-
tion of the study medication 
 Breastfeeding women 
 Immunocompromised patients 
 Patients with a known hypersensitivity to olaparib or any of the ex-
cipients of the product 
 
 Patients with known active hepatitis due to risk of transmitting the 
infection through blood or other body fluids 
 Previous allogeneic bone marrow transplant 
 Whole blood transfusions in the last 120 days prior to entry to the 
study 
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Characteristics 
 
  
Intervention 
n = 260 
 
Control 
n = 131 
 Median age (range), years 53.0 (29–82) 53.0 (31–84) 
 Response after platinum-
based chemotherapy, n (%) 
   Clinical CR 
   PR 
 
 
213 (81.9) 
47 (18.1) 
 
 
107 (81.7) 
24 (18.3) 
Number of cycles of plati-
num-based chemotherapy, n 
(%) 
   4 
   5 
   6 
   7 
   8 
   9 
 
 
 
2 (0.8) 
2 (0.8) 
198 (76.2) 
17 (6.5) 
18 (6.9) 
23 (8.8) 
 
 
 
0 (0.0) 
1 (0.8) 
106 (80.9) 
10 (7.6) 
7 (5.3) 
7 (5.3) 
ECOG performance status, n 
(%) 
   0 
   1 
   Missing 
 
 
200 (76.9) 
60 (23.1) 
0 
 
 
105 (80.2) 
25 (19.1) 
1 (0.8) 
Primary tumour location, n 
(%) 
   Ovary 
   Fallopian tubes 
   Primary peritoneal 
   Other 
 
 
220 (84.6) 
22 (8.5) 
15 (5.8) 
3 (1.2) 
 
 
113 (86.3) 
11 (8.4) 
7 (5.3) 
0 (0.0) 
FIGO stage, n (%) 
   III 
   IV 
 
220 (84.6) 
40 (15.4) 
 
105 (80.2) 
26 (19.8) 
Baseline CA-125 level, n (%) 
   ≤ULN 
   <ULN 
   Missing 
 
247 (95.0) 
13 (5.0) 
0 (0.0) 
 
123 (93.9) 
7 (5.3) 
1 (0.8) 
Histology, n (%) 
   Serous 
   Endometrioid 
   Mixed serous 
/endometrioid 
 
246 (94.6) 
9 (3.5) 
 
5 (1.9) 
 
130 (99.2) 
0 
 
1 (0.8) 
BRCA mutation, n (%) 
   BRCA1 
   BRCA2 
   Both BRCA1 and 
  BRCA2 
 
191 (73.5) 
66 (25.4) 
3 (1.2) 
 
91 (69.5) 
40 (30.5) 
0 
BRCA mutation status, n 
(%) 
   Myriad/BGI-confirmed  
   germline BRCA-mutation 
   FMI-confirmed somatic  
   BRCA mutation 
 
 
 
257 (98.8) 
 
2 (0.8) 
 
 
 
131 (100.0) 
 
0 
History of cytoreductive 
surgery, n (%) 
   Upfront surgery 
      Residual macroscopic  
      disease 
      No residual macroscopic  
      disease 
      Unknown 
   Interval cytoreductive sur-
gery 
      Residual macroscopic  
      disease 
      No residual macroscopic  
      disease 
   No surgery 
 
 
161 (61.9) 
 
37 (23.0) 
 
123 (76.4) 
1 (0.6) 
 
94 (36.2) 
 
18 (19.1) 
 
76 (80.9) 
4 (1.5) 
 
 
85 (64.9) 
 
22 (25.9) 
 
62 (72.9) 
1 (1.2) 
 
43 (32.8) 
 
7 (16.3) 
 
36 (83.7) 
3 (2.3) 
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Applicability of evidence 
Population 
The SOLO1 trial population included patients with newly diagnosed, advanced ovarian cancer, fal-
lopian tube cancer or primary peritoneal cancer with a BRCA1/2 mutation and a CR or PR after plat-
inum-based chemotherapy, representing a highly selected trial population. The median age of trial 
patients of 53 years stands in contrast to a median age at diagnosis of 63 years (ovarian cancer is 
most frequently diagnosed among women aged 55 to 64 years) [12]. Almost 80% of the patients of 
the olaparib group had an ECOG performance status of 0, meaning that the women were able to 
carry on normal activity. 
Intervention 
The mode of administration and dosing of olaparib in SOLO1 trial patients was consistent with the 
FDA-approved license [8]. The patients received olaparib until investigator-assessed objective dis-
ease progression on imaging (according to RECIST, version 1.1) provided that the patients were 
having a benefit and did not meet any discontinuation criteria. Patients who had no evidence of 
disease at 2 years stopped the trial intervention; patients who had a PR at 2 years were permitted 
to continue olaparib in a blinded manner. 
Comparators 
In the SOLO1 trial, a placebo was selected as comparator. For direct comparison, different PARP in-
hibitors, including rucaparib and niraparib, may be appropriate.  
Outcomes 
There is evidence that the risk of disease progression or death was 70% lower in patients who re-
ceived olaparib as compared to patients who received placebo. The applicability of results is limited 
due to the fact that final analysis data are lacking, and the presented data are primary/interim 
analysis data. 
Setting 
The SOLO1 trial is an international trial including patients from 15 countries. No issue regarding 
setting applicability was found. 
Abbreviations: BRCA = breast cancer susceptibility gene, CR = complete response, ECG =electrocardiogram, ECOG = Eastern Cooperative 
Oncology Group, FACT-O = Functional Assessment of Cancer Therapy – Ovarian, FDA = U.S. Food and Drug Administration, FIGO = 
International Federation of Gynecology and Obstetrics, FMI = Foundation Medicine, HR = hazard ratio, HRQoL = Health-related quality of life, 
ITT = intention-to-treat, IV = intravenous, n = number, NR = not reported, OS = overall survival, PFS = progression-free survival, PFS2 = 
second progression-free survival, PR = partial response, RECIST = Response Evaluation Criteria in Solid Tumours, TOI = trial outcome index, 
ULN = upper limit of normal 
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Table 6: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [5, 17] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: Randomisation was performed centrally 
with a block design, with stratification according to clinical response after platinum-based 
chemotherapy (complete or partial). 
yes 
Adequate allocation concealment: Patients were assigned to a trial group through an interac-
tive Web-based or voice-response system. 
yes 
Blinding: 
double-blinded 
Patient: blinded yes 
Treating physician: blinded yes 
Selective outcome reporting unlikely: Reasons for discontinuations have been reported. No 
median PFS data were available. 
no 
No other aspects which increase the risk of bias: The trial was designed by the first and last 
authors in collaboration with the manufacturer and the Gynecologic Oncology Group. Astra-
Zeneca was responsible for overseeing the collection, analysis, and interpretation of the data. 
The manuscript was written by the authors, with medical writing assistance funded by Astra-
Zeneca and Merck. Olaparib is being co-developed by AstraZeneca and Merck, and Merck pro-
vided input regarding the interpretation of the data. 
no 
Risk of bias – study level high 
 
 
 
